P95

What P95 does

P95 is a Belgium-headquartered, full-service Contract Research Organization (CRO) specializing in clinical trials and epidemiological research for vaccines and infectious diseases. Founded in 2011 by Thomas Verstraeten (former VP of vaccines at GSK), the company operates across five continents with regional hubs in Europe (Belgium, France, Austria, Netherlands), Africa (South Africa, Kenya, Ghana, Morocco), Latin America (Colombia), North America (North Carolina), and Southeast Asia (Thailand). The service portfolio spans four core areas: Phase I-IV clinical trial delivery, epidemiology and real-world evidence (RWE) studies, specialized Africa and LMIC clinical research, and data management/biostatistics/safety/medical writing. Proprietary and partnered platforms include the id.DRIVE platform (used for COVID-19 vaccine effectiveness studies against variants including JN.1) and the DRIVE influenza vaccine effectiveness framework, which underpins the COVIDRIVE public-private consortium.

The business model is professional services B2B, generating revenue through project-based contracts with pharmaceutical and biotech companies, international health organizations (WHO, Gates Foundation, CEPI), and public health agencies. Pricing is project-specific and quote-based with no public disclosure. Customer concentration is spread across major vaccine manufacturers (AstraZeneca, GSK, Janssen, Sanofi-Pasteur, CureVac), international funders, and government research bodies. Distribution is via direct enterprise sales, supplemented by thought leadership through scientific publications, webinars, the Contagious Thinking podcast, and presence at conferences such as the World Vaccine Congress.

Since May 2023, P95 has been backed by healthcare-focused private equity firm Ampersand Capital Partners. Under PE ownership the company has executed a roll-up strategy: acquiring Pallas Health Research (Netherlands, 2021), merging with OnQ Research (South Africa, 2023), acquiring 4Clinics (Belgium/France, 2024) and Assign DMB (Austria, 2024), and merging with Julius Clinical (Netherlands, November 2025). The Julius Clinical merger transformed P95 from a ~300-person vaccine/infectious disease specialist into a 500+ person global full-service CRO spanning vaccines, infectious diseases, neuroscience, and cardio-renal-metabolic diseases. The combined organization is led by CEO Bassem Saleh, with founder Thomas Verstraeten transitioning to Board Member and Senior Advisor.

Name

P95

Legal name

P95 CVBA

Website

http://www.p-95.com/

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

P95 is a Belgium-based full-service CRO specializing in clinical trials, epidemiology, and real-world evidence for vaccines and infectious diseases, serving pharmaceutical companies, international health organizations, and government agencies across 40+ countries and 5 continents.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Clinical research services
• Vaccine development CRO
• Infectious disease trials
• Real-world evidence studies
• Epidemiology consulting

Headquarters

HQ city

Heverlee

HQ country

Belgium

HQ region

Europe

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Trial Services: Full-service CRO providing Phase I-IV clinical trial support for vaccines and infectious diseases, including study design, site identification, trial management, and regulatory compliance. Revenue generated through service contracts with pharmaceutical companies, biotech firms, and public health organizations.
2. Epidemiology and Real-World Evidence Studies: Non-interventional studies and real-world data analysis for vaccines and infectious diseases, generating insights into disease burden, vaccine effectiveness, treatment outcomes, and healthcare resource utilization.
3. Data Management, Biostatistics, and Medical Writing: Data management, biostatistics, safety management, and medical writing services ensuring data integrity and insightful analysis across all stages of drug and vaccine development.
4. Vaccine Development Consulting: Consulting services supporting vaccine development including regulatory affairs, pharmacovigilance, and scientific strategy.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

P95 is a full-service Contract Research Organization (CRO) delivering Phase I-IV clinical trial services, epidemiology and real-world evidence studies, data management/biostatistics/safety/medical writing, and vaccine development consulting for pharmaceutical, biotech, and public health clients. Its core offering emphasizes vaccine and infectious disease research, with deep operational presence in Africa and LMICs, and serves clients such as AstraZeneca, GSK, Janssen, Sanofi-Pasteur, WHO, and the Bill & Melinda Gates Foundation.

Product overview

P95 is a full-service Contract Research Organization (CRO) specializing in vaccine development and infectious diseases. The company offers an integrated suite of services including Clinical Trial Delivery, Epidemiology and Real-World Evidence (RWE) Solutions, Africa and LMICs Services, and Data, Analysis, Safety and Writing. The core platform is enhanced through strategic acquisitions (4Clinics, Assign DMB, Pallas Health Research) and mergers (OnQ Research, Julius Clinical). P95 operates across five continents with operations in neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. The company provides end-to-end clinical research support from Phase I-IV clinical trials to epidemiological studies and non-interventional studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Delivery Comprehensive clinical trial solutions for vaccines and infectious diseases, guiding projects from early to late phase trials and ensuring high-quality results that meet regulatory and global standards. The service is for pharmaceutical, biotech, and public health clients conducting vaccine and infectious disease development programs.
• Epidemiology and Real-World Evidence (RWE) Solutions Comprehensive epidemiology and RWE solutions for vaccines and infectious diseases, supporting design and execution of non-interventional studies and real-world data analysis for generating insights into disease burden, vaccine effectiveness, treatment outcomes, and healthcare resource utilization. For pharmaceutical companies, biotech firms, and public health organizations.
• Africa and LMICs Clinical Research Services Clinical and epidemiological research services specialized for Africa, low-and-middle-income countries (LMICs), and other underserved regions, combining global standards with localized expertise for successful project delivery in challenging environments. For sponsors running trials in Africa and LMICs.
• Data, Analysis, Safety and Writing Data management, biostatistics, safety management, and medical writing services ensuring data integrity and insightful analysis for vaccines and drugs across all stages of development — from protocol writing, eCRF design and database management to pharmacovigilance, complex statistical reporting, regulatory compliance, and publications. For pharmaceutical and biotech sponsors.
• id.DRIVE Vaccine Effectiveness Platform Proprietary platform used for vaccine effectiveness studies, including COVID-19 brand-specific effectiveness analysis and influenza vaccine effectiveness studies. Underpins P95's brand-specific vaccine effectiveness work for sponsors including AstraZeneca, GSK, Janssen, Sanofi-Pasteur, and CureVac via the COVIDRIVE consortium.

Quantifiable outcome

• 1000+ clinical trials completed across Phase I-IV
• +2 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and supporting.

• Julius ClinicalcoreStrategic or Co-development Partner · 19 November 2025Leading clinical CRO specializing in CNS, cardio-metabolic, renal, and rare diseases, headquartered in Zeist, Netherlands. P95 and Julius Clinical merged in November 2025 to form a 500+ person global CRO with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines.
• BiovaccoreStrategic or Co-development Partner · 1 November 2025South African biotech company developing the OCV-S cholera vaccine - the first vaccine developed entirely in Africa. P95 serves as the selected CRO for the landmark cholera vaccine clinical trial launched November 2025.
• International Vaccine Institute (IVI)coreStrategic or Co-development Partner · 1 November 2025International organization supporting the OCV-S cholera vaccine clinical trial in South Africa, partnering with Biovac, SAMRC, and P95.
• South African Medical Research Council (SAMRC)coreStrategic or Co-development Partner · 1 November 2025Government health research organization collaborating on the OCV-S cholera vaccine trial as part of the partnership with Biovac, IVI, and P95.
• LatinaBAsupportingStrategic or Co-development Partner · 29 January 2025Regional CRO with over 15 years conducting clinical trials in Latin America. Strategic partnership aimed at propelling vaccine and infectious disease research in the region by combining P95's global expertise with LatinaBA's regional knowledge.
• Assign DMBcoreStrategic or Co-development Partner · 5 September 2024Austrian CRO founded in 2005 by Dr. Anton Klingler, specializing in clinical data management, biostatistics, safety, and project management. Based in Innsbruck with 20+ years of experience, acquired by P95 in September 2024.
• 4ClinicscoreStrategic or Co-development Partner · 1 July 2024Belgian CRO founded in 1997, specializing in data management, biostatistics, medical writing, regulatory affairs, and clinical operations with focus on vaccines, immunotherapeutics, and medical devices. Fully integrated into P95 from July 1, 2024.
• OnQ ResearchcoreStrategic or Co-development Partner · 1 October 2023South African-based CRO founded in 1999, specializing in clinical trials across Africa. Merged with P95 in October 2023 to strengthen vaccine development capabilities and expand presence in emerging geographies, particularly Africa.
• COVIDRIVE ConsortiumcoreStrategic or Co-development Partner · 22 July 2021Public-private partnership evaluating COVID-19 vaccine effectiveness in Europe. P95 is a coordinating partner alongside AstraZeneca, CureVac, Janssen, Sanofi-Pasteur, GSK, FISABIO, and THL. Leverages existing DRIVE influenza vaccine effectiveness platform.
• Pallas Health Research and ConsultancysupportingStrategic or Co-development Partner · 13 April 2021Dutch research and advisory organization specializing in epidemiology and health research, based in Rotterdam. Founded in 1999 by Judith van den Bosch with 12 epidemiologists. Acquired by P95 in April 2021.

Scale indicators8 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Medpace: Mid-to-large full-service CRO known for therapeutic specialization (including infectious disease) and an owner-operator model. Comparable to P95 in being a science-led, mid-sized CRO with strong sponsor relationships.
• Syneos Health: Global full-service CRO with vaccine and infectious disease trial experience across Phase I-IV. Comparable in providing biopharmaceutical development services with combined clinical and real-world evidence offerings.
• Parexel: Global CRO with significant vaccine and infectious disease experience, plus real-world evidence capabilities. Comparable in providing full-service clinical development for pharma and biotech.
• IQVIA: Largest global CRO with extensive vaccine and infectious disease trial capabilities, real-world evidence platforms (e.g., IQVIA's vaccine effectiveness studies), and integrated clinical operations across 100+ countries — directly comparable to P95's full-service, multi-region model.
• Worldwide Clinical Trials: Mid-sized global CRO focused on complex clinical trials across multiple therapeutic areas including vaccines and infectious diseases. Comparable in scale and therapeutic focus to P95.
• Charles River Laboratories: Global CRO with vaccine and infectious disease expertise via its Research Models & Services and contract development segments. Comparable in providing scientific and clinical research services to vaccine developers.
• ICON plc: Global full-service CRO with Phase I-IV clinical trial capabilities across vaccines, infectious diseases, and multiple therapeutic areas. Comparable as a multi-region, multi-therapeutic CRO serving Big Pharma and biotech.

Broad incumbents

• Labcorp Drug Development: Large CRO and central laboratory business offering Phase I-IV services, vaccine testing, and real-world evidence. Comparable as a broader incumbent with vaccine/infectious disease capabilities overlapping P95's focus.
• PPD (Thermo Fisher Scientific): Global CRO owned by Thermo Fisher with extensive vaccine and infectious disease trial experience and integrated laboratory services. Comparable as a full-service CRO with broader scientific breadth than P95.
• Eurofins Scientific: Global testing and contract research services provider with central laboratory, vaccine testing, and clinical trial support capabilities. Comparable as an adjacent, broader-scope provider of laboratory and clinical research services to vaccine developers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/p95
• Xx.com/P95epidemiology

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about P95